André-Guy Martin
Chercheur associé
Axe Oncologie
Publications
View all-
article Nabid A, Carrier N, Vigneault É and Martin AG, Nguyen TV, Bahary JP, Vavassis P, Bahoric B, Brassard MA, Archambault R, Vincent F, Bettahar R, Duclos M, Wilke D, Souhami L
Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data
Int J Radiat Oncol Biol Phys 2025.
-
article Spyrou A, Martin AG, Hannoun-Lévi JM, Stewart A
Measuring patient reported outcomes in brachytherapy: Why we should do it and more importantly how
Clin Transl Radiat Oncol 49 2024.
-
article Nabid A, Carrier N, Martin AG, Bahary JP, Vavassis P, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, Souhami L
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
Qual Life Res 34 (3), 2025.
Projects
- Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer (2SHARP), from 2025-03-14 to 2027-03-13
- Création de la base de données intégrée PRECISE-LDR (PRostatE Cancer Integrated data SEt-LDR), from 2025-04-01 to 2028-04-01
- Création d’un outil d’intelligence artificielle visant la prédiction des toxicités des patients traités par radiothérapie en contexte de cancers de la prostate (PROstate Toxicity Evaluation and Control Through AI – PROTECTA-LDR)., from 2025-06-24 to 2026-03-31
- The impact of Monte Carlo dose calculations on prostate and breast low-dose rate brachytherapy dose-outcome relationships and radiobiological modeling, from 2020-10-01 to 2025-09-30
- A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN), from 2022-04-01 to 2025-02-28
- 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , from 2024-06-19 to 2025-03-31